Trial · NCT05497323
Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA
NCT05497323, Phase 1, Unknown, Dr.dr.Irma Bernadette, SpKK (K)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA. Trials, record NCT05497323. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05497323
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA
- NCT number
- NCT05497323
- Status
- Unknown
- Phases
- Phase 1
- Enrollment
- 284 participants, actual
- Lead sponsor
- Dr.dr.Irma Bernadette, SpKK (K)
- Conditions
- Acne Vulgaris
- Interventions
- Combination Cream, Adapalene 0,1% cream
- First posted
- 2022-08-11
- Last updated
- 2023-04-06
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of acne severity | re-evaluation on day 28 and day 56 of therapy | Based on Global Acne Severity Scale (GEA Score). On a scale of 0-5, 0 indicates almost no lesions, while 5 indicates severe acne. |
| Primary | Change of acne severity | re-evaluation on day 28 and day 56 of therapy | Based on Indonesia Acne Expert Meeting (IAEM score). The scale consists of mild, moderate, and severe. |
| Primary | Change of Level Of Seborrhea | re-evaluation on day 28 and day 56 of therapy | The level of seborrhea is assessed subjectively by participants on a scale of 0 (minimum level) - 10 (maximum level) |
| Primary | Change of erythema | re-evaluation on day 28 and day 56 of therapy | Based on Clinician Erythema Assessment Scale (CEA) to assess the degree and extent of erythema. The scale ranges from 0-5; 0 indicates no erythema, while 4 indicates severe erythema. |
| Primary | Change of quality of life | re-evaluation on day 28 and day 56 of therapy | Assessed using Cardiff Acne Disability Index. Cardiff Acne Disability Index questionnaire is an instrument to measure the quality of life of acne vulgaris patients. This instrument has 5 self-answered questions by the patient (for subjects aged≥ 18 years). |
| Primary | Change of quality of life | re-evaluation on day 28 and day 56 of therapy | Assessed using Acne-Quality of Life. Acne-QoL is an instrument consisting of 19 questions divided into 4 categories: self-perception, social relationships, emotional effects, and acne symptoms. The total score of Acne-QoL is 0-114. The higher total score for each category obtained will interpret that the quality of life of acne vulgaris patients is getting better. |
| Primary | Facial Analysis Examination With Janus Facial Analysis System | re-evaluation on day 28 and day 56 of therapy | Assessed using the Janus Facial Analysis System®. Janus Facial Analysis System will issue data related to the patient's facial condition. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05497323
GET https://conductscience.org/api/trials/v1/NCT05497323/registered